Free Trial
NASDAQ:AEON

AEON Biopharma Earnings Date & Estimates

AEON Biopharma logo
$0.23 -0.01 (-4.53%)
Closing price 04:00 PM Eastern
Extended Trading
$0.24 +0.00 (+2.16%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AEON Biopharma is estimated to report earnings on Friday, November 13, 2026.

What Analysts Expect from AEON Biopharma

AEON Biopharma is expected to post earnings of -$0.10 per share. AEON Biopharma last reported on August 12, 2024, posting -$11.52 per share and beating the -$13.68 consensus estimate.

Consensus Estimates

Consensus EPS
-$0.10

Recent Track Record

Last Reported
Q2 2024
Last Quarter EPS
-$11.52 (Beat by +$2.16)

AEON Biopharma Earnings FAQ

AEON Biopharma (NASDAQ:AEON) is estimated to report earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect AEON Biopharma to post earnings of -$0.10 per share for the quarter.

AEON Biopharma Earnings Headlines

Zacks Research Forecasts AEON Biopharma Q3 Earnings
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
See More AEON Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AEON Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AEON Biopharma and other key companies, straight to your email.

About AEON Biopharma

AEON Biopharma (NASDAQ:AEON) is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxin. Unlike companies that primarily target aesthetic uses, AEON is developing treatments for neurological and other medical conditions in which botulinum toxin may provide therapeutic benefits.

The company’s lead product candidate is ABP-450, an investigational botulinum neurotoxin type A complex licensed from Daewoong Pharmaceutical. AEON has evaluated ABP-450 in clinical programs targeting conditions including chronic migraine and cervical dystonia, and its broader development strategy may encompass additional therapeutic indications. ABP-450 has not received regulatory approval for these uses.

AEON Biopharma became a publicly traded company through a business combination with Priveterra Acquisition Corp. in 2023 and is headquartered in Irvine, California. The company’s programs are intended for markets in the United States and other international jurisdictions, subject to clinical results and regulatory approvals. Marc Forth serves as the company’s president and chief executive officer.

View AEON Biopharma Profile